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Abstract
Hereditary myopathies are inherited disorders primarily affecting the skeletal muscle tissue.
These are causedbymutations indifferent genes-encodingproteins that play important roles in
muscle structure and function. Skeletal muscle weakness and hypotonia are typical clinical
manifestations in most of hereditary myopathies. Histological features such as fiber type
disproportion,myofibrillar disorganization, and structural abnormalities are usually observed
in muscle biopsies of non-dystrophic myopathies, while fibrosis, fiber regeneration, wasting,
and atrophy are characteristic of dystrophic myopathies. However, similar histopathological
featuresmay overlap in different hereditarymyopathies. This is howmutations in a same gene
can lead to different forms of hereditary myopathies and a same myopathic phenotype can
derive from defects in different related genes making difficult a specific diagnosis. In this
regard, understanding all aspects of hereditary myopathies can facilitate a better diagnosis
and treatment. In this chapter, we offer a review of some of the most prevalent hereditary
myopathies, highlighting clinical, histological, andmolecular aspects of thesemuscledisorders.
Keywords: hereditary myopathy, muscle disease, congenital myopathy, muscular
dystrophy
1. Introduction
Hereditary myopathies are a heterogeneous group of inherited diseases primarily affecting the
skeletalmuscle tissue.These are causedbymutations ingenes encodingproteins critical formuscle
structure and function, with X-linked, autosomal-recessive or -dominant inheritance pattern.
Hereditary myopathies include several forms of dystrophic and non-dystrophic disorders with a
wide spectrumof genetic, biochemical, histological, and clinical features.A commoncharacteristic
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Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
is the presence of hypotonia and progressive or non-progressive muscle weakness. The onset of
hereditarymyopathies is commonlyat birth, although theymaybecome evident later in childhood
or adulthood. Clinical severity is variable being the early-onset forms usually more severe [1].
Diagnosis of hereditarymuscle diseases involve physical and neurological evaluation, electromy-
ography and nerve conduction studies (EMG andNCS), magnetic resonance imaging, blood tests
including creatine kinase levels (CK), which typically rises in muscle damage and histopatholog-
ical makers in muscle biopsies [1]. Advances in molecular genetics have allowed identifying an
increasing number of genes linked to different forms of hereditarymyopathies in the last decades.
With this, it has become evident that mutations in a same gene can lead to more than one
pathological and clinical phenotype as well as the same pathological feature can result from
mutations in different genes. Given this overlap in genetic, clinical, and histological features, the
use of different approaches is critical for a proper diagnosis.
This chapter aims to summarize clinical, histological, and molecular aspects of some inherited
forms of muscle disease, providing a general overview of the most prevalent hereditary
myopathies, including congenital, mitochondrial, and metabolic myopathies, myotonia, and
muscular dystrophies. The information discussed in this chapter is resumed in Table 1.
Hereditary
myopathy
Genes/proteins Mechanism
affected
Histopathological
features
Clinical features
Non-dystrophic
Nemalin myopathy NEB/nebulin
ACTA/skeletal muscle alpha-
actin
TPM3/alpha-tropomyosin-3
TPM2/beta-tropomyosin-2
TNNT1/troponin T1
CFL2/cofilin-2
KBTBD13/Kelch-repeat-and-
BTB-domain-containing-13
KLHL40/Kelch-like-family-
member-40; KLHL4
KLHL41/Kelch-like-family-
member 41
LMOD3/leiomodin-3
MYPN/myopalladin
Structural
disorganization of
sarcomere units
Rod inclusions Hypotonia,
proximal weakness,
respiratory
insufficiency in the
most severe cases
Core myopathy
(Central and multi-
minicore)
RYR1/ryanodine receptor
SEPN1/selenoprotein N
EC-uncoupling
Defects in Ca2+ and
redox homeostasis
Cores and/or
multiminicores
Hypotonia,
proximal weakness,
delayed motor
milestones and
orthopedic
complications.
Malignant
hyperthermia
susceptibility
Centronuclear
myopathy/
myotubular
myopathy (XLMTM)
MTM1/myotubularin
DNM2/dynamin-2
BIN1/amphiphysin-2
RYR1/ryanodine receptor
channel
Defects in
membrane
remodeling and
intracellular
trafficking
Nuclei
centralization
Necklace fibers
Proximal and distal
muscle weakness,
delayed acquisition
of motor milestones,
difficulty to walk
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Hereditary
myopathy
Genes/proteins Mechanism
affected
Histopathological
features
Clinical features
TTN/titin
SPEG/striated muscle
preferentially expressed
protein kinase
and climb stairs.
Facial muscles
involvement
typically presenting
ptosis and
ophthalmoplegia.
Persistent
hypotonia and
respiratory muscles
failure in the most
severe cases of
XLMTM.
Congenital fiber-type
disproportion
myopathy
TPM3/alpha-tropomyosin-3
ACTA/skeletal muscle alpha-
actin
RYR1/ryanodine receptor
channel
Defects in acto-
myosin interaction
Defects in EC-
coupling
Prevalence and
hypotrofia of type 1
fibers (5-40%
smaller than type 2)
Mild to severe
weakness mainly in
shoulders, upper
arms, hips, and
thighs musculature
and in face muscles;
orthopedic
complications and
joint contractures .
Respiratory muscle
hypotonia is
observed in some
cases.
Myosin storage
myopathy
MYH7/slow-skeletal/β-cardiac
myosin heavy chain
Defects in myosin
folding
Impaired
sarcomere thing
filament assembly
Hyalin bodies Hypotonia,
proximal muscle
weakness, delayed
acquisition of motor
milestones,
respiratory
insufficiency
secondary and
cardiac involvement
may occur in some
cases.
Mitochondrial
myopathy
Cytochrome b/cytochrome c
oxidase
Q10 Coenzyme
TK2/thymidine kinase
POLG1/polymerase gamma 1
Dysfunction of the
respiratory chain
and energy
production
Sub-sarcolemmal
and
intermyofibrillar
accumulation of
mitochondria;
“ragged blue/red
fibers”
Typically are
multisystem
disorders with
predominant
involvement of
muscles and nerves.
Myalgia, fatigue,
exercise intolerance,
proximal and distal
muscle weakness
and slowly
progressive paresis
of the extra ocular
muscles. Marked
hypotonia,
respiratory muscle
weakness and
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Hereditary
myopathy
Genes/proteins Mechanism
affected
Histopathological
features
Clinical features
feeding difficulty in
most severe cases.
Metabolic myopathy
(glycogen storage
disease)
GAA/lysosomal enzyme acid
α-glucosidase
AGL/glycogen-debranching
enzyme
PYGM/myophosphorylase
Defects in glycogen
hydrolysis and
energy production
Basophilic/PAS
positive vacuoles
cytosolic inclusions
Generalized muscle
weakness and
hypotonia, fatigue
and exercise-
induced myalgia,
cardiac and
respiratory failure
in most severe cases
Metabolic myopathy
(lipid storage disease)
SLC22A5/carnitine transporter
OCTN2
ETF/electron-transfer
flavoprotein
ETFH/ETF-dehydrogenase
PNPLA2/adipose triglyceride
lipase
Fatty acid
dysmetabolism and
defects in energy
production
Increased number
and size of lipid
droplets and
neutral-lipid
containing vacuoles
inside muscle fibers
Hypotonia, muscle
weakness and
cardiomyopathy
systemic disorders
are often observed
including
encephalopathy,
hepatomegaly,
hypoglycemia, and
metabolic acidosis
Congenital myotonia ClC1/skeletal muscle chloride
channel
Reduced chloride
conductance
Enhanced
sarcolemmal
excitability
Predominance and
hypotrophy of type
2 fibers, increased
endomysial
connective tissue
and tubular
aggregates are
usually observed
-
Myotonia, myalgia,
transient episodes
of generalized
weakness and
muscular
hypertrophy
Paramyotonia
congenita
SCN4A/alpha-subunit of the
skeletal muscle sodium
channel
Abnormal
persistent
sarcolemmal
sodium currents
Early-onset
generalized
weakness and
“myotonic
discharges” and
extreme sensitivity
to cold
Dystrophic
Myotonic dystrophy
(DM1/DM2)
DMPK/myotonin-protein-
kinase (CTG repeat expansion)
ZNF9/zinc finger 9 (CCTG
repeat expansion)
Deregulation of
RNA-binding
proteins, toxic
nuclear foci and
impair gene
expression
Central nuclei, type
1 fiber atrophy,
regenerating fibers,
fibrosis and adipose
deposition.
Atrophic type 2
fibers with pyknotic
nuclear clumps are
specifically
observed in DM2
Muscle wasting,
progressive
weakness,
myotonia, cataracts,
and multi-organ
involvement
affecting heart,
brain, and
endocrine system
Duchenne and Becker
muscular dystrophy
DMD/dystrophin Defects in DGC ,
mechanical stress
during muscle
contraction,
sarcolemmal
damage and
Muscle fiber
necrosis,
regeneration,
fibrosis and
atrophy, nuclei
internalization,
Inflammatory
Early-onset
dystrophy, delayed
acquisition of motor
milestones and
rapid progression of
muscle weakness
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Hereditary
myopathy
Genes/proteins Mechanism
affected
Histopathological
features
Clinical features
abnormal Ca2+
homeostasis
response and
elevated serum
levels of CK are
typically observed
that usually leads to
wheelchair needing.
LGMD1 MYOT/myotilin
LMNA/lamin A/C
CAV3/caveolin3
DNAJB6
DES/desminTNPO3/
transportin3
HNRPDL
Defects in
sarcomere integrity,
nuclear
maintenance and
gene regulation
among others
Muscle fiber
necrosis,
regeneration,
fibrosis and
atrophy, nuclei
internalization,
Inflammatory
response and
elevated serum
levels of CK are
typically observed
Proximal and distal
weakness, calf
hypertrophy,
cramps associated
to exercise and
respiratory and
cardiac involvement
in some cases
LGMD2 CAPN3/calpain3
DYSF/dysferlin
alpha-sarcoglycan
beta-sarcoglycan
gamma-sarcoglycan
delta-sarcoglycan
TCAP/telethonin
TRIM32
FKRP/fukutin-related-protein
POMT1/O-mannosyl-
transferase 1
FKTN/fukutin
POMT2/O-mannosyl-
transferase 2
POMGnT1/O-linked-mannose
beta-1,2-N-
acetylglucosaminyltransferase
1 DAG1/dystroglycan gene
TTN/titin
ANO5/anoctamin5
PLEC1/plectin
DES/desmin
TRAPPC11/transport protein
particle complex 11 gene
GMPPB/GDP-mannose
pyrophosphorylase B
ISPD/isoprenoid synthase
domain containing
GAA/lysosomal enzyme acid
α-glucosidase
LIMS2/PINCH2/senescent cell
antigen-like-containing
domain protein 2 gene
POPDC1/Popeye-domain-
containing 1
TOR1AIP1/lamina-associated
polypeptide 1B
POGLUT1/O-
glucosyltransferase 1
Defects in
sarcomere
organization and
maintenance,
defects in DGC
function and
sarcolemmal repair,
impaired
intracellular
trafficking , among
others
Raising in serum
CK, nuclei
internalization
wasting and
regeneration of
muscle fibers,
inflammatory
infiltrates in some
cases
Progressive
weakness and
atrophy of the
shoulder and pelvic
girdle musculature
with cardiac and
respiratory muscles
involvement in
some cases
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2. Congenital myopathies
Congenital myopathies are genetic neuromuscular disorders characterized by typical histo-
pathological alterations including type-1 fibers predominance and hypotrophy and presence
of structural abnormalities such as rod-inclusions and cores, among others [1]. Their clinical
Hereditary
myopathy
Genes/proteins Mechanism
affected
Histopathological
features
Clinical features
Congenital muscular
distrophies
LAMA2/merosin/laminin-α2
chain
COL6A1/COL6A2/COL6A3/
collagen 6A
POMT1/O-mannosyl-
transferase 1
POMT2/O-mannosyl-
transferase 2
Defects in DGC
function and cell
matrix integrity
Variation of fiber
size, whorled and
split fibers, nuclei
internalization
increase of
connective and
adipose tissue
Generalized
hypotonia and
predominantly
proximal weakness,
joint contractures,
cardiomyopathy,
respiratory failure
and central nervous
system
involvement, retinal
and brain
malformations in
the most severe
cases
Facioscapulohumeral
musular dystrophy
DUX4/double homeobox 4 Toxic “gain of
function” of the
normally repressed
transcriptional
regulator DUX4
Dystrophic features
including fibrosis,
muscle fiber
hypertrophy ,
central nucleation
and endomysial
inflammation
Slowly progressive
asymmetric and
descending
weakness, initially
affecting face
(facio), scapula
(scapulo) and upper
arms (humeral),
followed by
weakness of the
distal lower
extremities and
pelvic girdle
Emery-dreifuss
muscular dystrophy
EMD/emerin
LMNA/lamin A/C
Nuclear envelope
defects, impair in
gene expression,
cell signaling and
chromatin
architecture
Dystrophic features
such as fiber size
disproportion,
nuclei
internalization,
increase of
endomysial
connective tissue,
necrosis and
regeneration are
usually observed.
Reduced expression
of emerin or lamin
A/C in muscle,
fibroblasts or blood
Slowly progressive
muscular weakness,
joint contractures,
spine rigidity and
heart disease
Table 1. Genetic, histological, and clinical aspects of hereditary myopathies.
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course is usually non-progressive or slowly progressive and their prognosis is mainly deter-
mined by the involvement of respiratory muscles. Unlike muscular dystrophies, patients with
congenital myopathy typically exhibit normal or discretely increased levels of CK [2]. The
onset of the disease generally occurs in the neonatal period and it has an estimated incidence
of 1:25,000 live births [1].
Clinically, congenital myopathies manifest with heterogeneous features such as generalized
weakness, hypotonia, hyporeflexia, and poor muscle bulk. Congenital myopathies also pre-
sents with dysmorphic characteristics, secondary to the myopathy such as pectus carinatum
(a chest malformation characterized by a protrusion of the sternum and ribs), scoliosis, joint-
contractures, foot deformities, high-arched palate, and elongated facies [3]. Different muta-
tions in a same gene can cause different phenotypic forms of congenital myopathy, whereas
mutations in different genes can induce muscle diseases with overlapping clinical and histo-
logical features, making difficult a specific diagnosis. However, based on the histological
markers observed in muscle biopsies, congenital myopathies can be divided in five forms:
nemaline myopathy, core myopathy, centronuclear myopathy, fiber-type disproportion myop-
athy, and myosin storage myopathy [1].
2.1. Nemaline myopathy
Nemaline myopathy (NM) is one of the three major types of congenital non-dystrophic myop-
athies with an estimated incidence of 1:50,000 [4]. Based on the severity and the onset of the
disease, NM can be divided in different subtypes ranging from severe forms with neonatal-
onset, which is usually lethal in the first months of life, to less severe forms with onset in the
childhood or adulthood [5] Clinically NM courses with hypotonia, weakness of proximal
skeletal muscles, including facial and neck flexor muscles that can lead to respiratory insuffi-
ciency and death in the most severe cases [4]. Less severe forms of NM exhibit a static or slowly
progressive weakness of the distal limbs, trunk, and facial muscles with a delay in the acqui-
sition of motor milestones. Cardiac muscles are usually not affected in NM [4].
Histologically, NM characterizes by the presence of nemaline-bodies or small “rod-like inclu-
sions.” These are thread-shape structures that stain red or purple by the modified Gömöri’s
trichrome staining [1] (Figure 1). Rod-inclusions vary from 1 to 7 μm of length and 0.3 to 2 μm
of width and, mainly, consist of actin and alpha-actinin accumulation, apparently product of
an alteration of the ratio of actin-binding proteins and their interaction [6]. At the light
microscopy, nemaline bodies appear like clusters localized at the cytoplasm and often at the
periphery of the muscle fibers, although they also can be located in the nucleus making
difficult to identify. At the ultrastructural level, rod inclusions appear like electron-dense
bodies at the Z-bands [1]. The presence of rod-like structures in the sarcomere apparatus
difficult the contractibility of muscles. It has been suggested that NM-linked mutations in
proteins that compose the sarcomere affect the arrangement of muscle fibers, hindering the
typical slid of the fibers during movement, and causing muscles to be unable to efficiently
contract [7] (Figure 2). However, although the presence of nemaline bodies is required for the
diagnosis of NM, they are just a product and are not necessarily the cause of the disease. In this
regard, myofibrillar dissociation and smallness appear to be a primary defect causing impaired
Hereditary Myopathies
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contractility and muscle weakness in NM [5]. Moreover, nemaline bodies can be observed in
other myopathies and in muscle degeneration related to aging [6].
NM is caused by mutations in 11 genes encoding proteins that compose or regulate the
sarcomere thin filaments. These are nebulin (NEB) [8], skeletal muscle alpha-actin (ACTA1)
[9], alpha-tropomyosin-3 (TPM3) [10], beta-tropomyosin-2 (TPM2) [11], troponin T1 (TNNT1)
[12], cofilin-2 (CFL2) [13], Kelch-repeat-and-BTB-domain-containing-13 (KBTBD13) [14],
Kelch-like-family-member-40 (KLHL40) [15], Kelch-like-family-member 41 (KLHL41) [16],
leiomodin-3 (LMOD3) [17] and myopalladin (MYPN) [18]. Most of these genes encode
sarcomeric proteins that are critical for the structural organization and function of the contrac-
tile apparatus. Therefore, NM-causing mutations can directly affect these functions, resulting
in skeletal muscle weakness. The most frequent mutated gene is nebulin (NEB) which account
for over 50% of the NM cases, all of them inherited in an autosomal-recessive way [8].Nebulin
is a giant actin-binding protein whose large size is proportional to the thin filament length.
Nebulin C-terminal region is anchored into the Z-disks and its N-terminal extends to the thin
filament pointed-end, acting as a “ruler” of the thin filament length for the sarcomere assem-
bly during myofibrillogenesis [19]. A great diversity of nebulin isoforms has been described,
which differ among various striated muscles types, developmental stages, and diseases [20].
Most nebulin mutations causing NM result in truncations or internal deletions and in a
Figure 1. Histopathological markers in hereditary myopathies. (A) Modified Gömöri’s trichrome stain showing rods in
nemaline myopathy. (B) SDH staining in central core disease due to RYR1 mutations. Note that cores are frequently
eccentric and that there are two or more in several fibers. (C) HE staining in a case of DNM2-related centronuclear
myopathy. Notice multiple centralized nuclei in some fibers and the radiating strands of intermyofibrillary network. (D)
Dystrophic changes in Emery-Dreyfus muscular dystrophy. There is a large variability on the size of the fibers, multiple
nuclei internalizations, increase of endomysial connective tissue, and foci of necrosis-regeneration, which define the
dystrophic pattern. (E) Modified Gömöri’s trichrome stain showing a ragged red fiber in mitochondrial myopathy. (F)
HE stain in McArdle’s disease. At the subsarcolemmal level large chromophobe vacuoles containing glycogen are shown.
Pictures in A and B are courtesy of Dr. Norma B. Romero, Institute of Myology, Paris, France; picture in panel C is
courtesy of Prof. Anders Oldfors, University of Gothenburg, Gothenburg, Sweden.
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reduction in the diversity of nebulin isoforms [6, 20], likely shortening thin-filaments length
during myofribillogenesis and disrupting muscle development.
Mutations in ACTA1 gene are linked to around 20% of the NM cases [9] which are predomi-
nantly inherited in an autosomal-dominant way [1]. Mutations in skeletal alpha-actin that cause
NM and other congenital myopathies are spread over different domains affecting primary actin
functions such as binding and hydrolysis of nucleotide, folding, F-actin polymerization and
stability, or its interaction with actin-binding proteins [21, 22].
Less prevalent mutations in TPM3 and TPM2 account for approximately 2–3% of the NM cases [1].
Tropomyosins are coiled-coil proteins that polymerize along actin filaments providing stability
and regulating the binding of the myosin heads to the thin actin filaments in the sarcomere (cross-
bridges), in a Ca2+-dependent way. NM-linked mutations in beta-tropomyosin-2 have shown to
Figure 2. Rod inclusions in the sarcomere. (A) A healthy sarcomere is schematized. (B) Rod inclusions in the sarcomere
are schematized. Rods are clustered near to the Z-line in the sarcomere of nemaline myopathy patients, affecting the
sarcomere arrangement and hindering contraction.
Hereditary Myopathies
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induce a reduction in actin-affinity and Ca2+ sensitivity [23] and to change the position of tropo-
myosin in the actin filaments, disorganizing the assembly of the actomyosin complex, reducing its
ATPase activity and leading to contractile dysfunction [24]. NM-causing mutations in TPM3 have
shown to suppress the expression of the slow alpha-tropomyosin-3 [25], likely deregulating
myosin-actin interaction and impairing the force-generating capacity of the sarcomere.
Mutations in the TNNT1 are less likely cause of NM. The troponin complex (troponin C,
troponin I, and troponin T) blocks the actin-myosin interaction, preventing contraction in resting
muscles. Specifically, troponin T binds to tropomyosins regulating the interaction of the troponin
complex with thin actin filaments. NM causing mutations in TNNT1 are mainly recessive, and
produce loss of the expression of troponin T in skeletal muscles [26] and reduction of
tropomyosin-binding affinity [27] likely impairing regulation of the muscle contraction.
Mutations in the CFL2 gene have shown to cause NM [13]. Cofilin2 is a skeletal muscle-specific
actin-depolymerizing factor, and NM-linked mutations significantly reduce the cofilin2 expres-
sion levels affecting actin dynamics likely causing its accumulation in the nemaline bodies [13].
More novel mutations in proteins that form part of the BTB/Kelch family have been linked to
several forms of NM. BTB/Kelch proteins are involved in a broad variety of cellular processes
including cytoskeleton modulation, gene transcription, ubiquitination, and myofibril assembly.
Dominant mutations in Kelch-repeat-and-BTB-domain-containing-13 (KBTBD13) produce a
mild form of NM with nemaline rods and core lesions ([14]. Autosomal-recessive mutations in
Kelch-like-family-member-40 (KLHL40), which seems to be critical for myogenesis and muscle
maintenance, cause a severe form of NM that includes fetal akinesia [15]. Recessive mutations in
Kelch-like-family-member 41 (KLHL41) associate with a severe NM phenotype with neonatal
death; NM-linked mutations cause destabilization of KLHL41 structural domains and reduce its
protein levels in skeletal muscle [16].
Leiomodin-3 (LMOD3) is a skeletal muscle-specific member of the tropomodulin family and
colocalizes with sarcomere thin actin filaments. Mutations in LMDO3 produce a severe form of
NM that manifests with absence of fetal movements, generalized hypotonia, and respiratory insuf-
ficiency. NMmutations abolish LMOD3 expression in skeletal muscle tissue of NM patients [17].
Mutations in myopalladin have been also recently identified to cause relatively mild forms of
NM with slowly progressive muscle weakness [18]. Myopalladin is a sarcomere protein local-
ized at the I-bands and Z-line that interacts with several sarcomeric components, including
nebulin, regulating sarcomere assembly [18]. NM-linked mutations in MYPN are loss of func-
tion mutations that markedly decrease the full-length protein levels likely affecting the main-
tenance of the sarcomeric organization [18].
2.2. Core myopathy
Core myopathies (CM) are heterogeneous congenital muscle diseases that present with hypo-
tonia and weakness of proximal muscles with a static or slow-progressive clinical course. CM
is the most common form of congenital myopathy [28]. Histologically, CM is characterized by
the presence of “cores,” large areas of abnormal myofibrillar arrangement and sarcomeric
Muscle Cell and Tissue - Current Status of Research Field90
disorganization, devoid of mitochondria, and oxidative-enzyme activity, which are mainly
found in type-1 muscle fibers (Figure 1). Cores can be single or multiple; and based on biopsy
observations, CM can be classified as central core disease (CCD) or multiminicore disease
(MmD) [28]. In CCD, single cores are centrally or eccentrically located along the longitudinal
axis of type 1 muscle fibers (Figure 1), while in MmD numerous short core lesions localize
diffusely throughout type 1 or type 2 muscle fibers [29]. Cores and rods lesions can occur
together in “core-rod myopathy,” a variant of NM [30]. Dominant-inherited CCD typically
courses with hypotonia and motor developmental delay in the childhood, presenting fetal
akinesia in the most severe cases [28]. Most mild forms manifest with myalgia, proximal
weakness with hip, girdle, and axial muscles involvement. Orthopedic complications includ-
ing hips dislocation, scoliosis, and foot deformities are also typical in CCD patients [28].
Clinical manifestations of MmD are highly variable. These range from a severe and most
prevalent neonatal form, which include axial muscle weakness, spinal rigidity, respiratory
impairment, and cardiac failures [31], to milder forms that course with generalized muscle
weakness predominantly affecting pelvic girdle [31].
CCD and MmD are caused by mutations in genes encoding two proteins involved in the
excitation-contraction (E-C)-coupling, calcium homeostasis, and redox regulation in muscle
fibers, these are the skeletal-muscle ryanodine receptor (RYR1) [32] and the selenoprotein N
(SEPN1) [31]. RyR1 is a functional calcium release channel that plays a critical role in the E-C
coupling by releasing calcium from the sarcoplasmic reticulum in response to conformational
changes induced by the activation of the voltage-sensing dihydopiridine receptor DHPR [33].
Most mutations in RyR1 gene are autosomal-dominant and associate with a CCD phenotype
[34]. Autosomal-dominant mutations in RyR1 mainly localizes in the C-terminal region, which
encodes the calcium release channel pore of the ryanodine receptor protein and in the
N-terminal region that includes the “foot” structure that interacts with DHPR [35]. An impor-
tant number of dominant mutations in RyR1 also associate to malignant hyperthermia suscep-
tibility (MHS), a pharmacogenetic predisposition to severe and potentially lethal episodes
induced by halogenated anesthetic agents (halothane, isofluorane) and succinylcholine [36].
MHS-linked mutations cause a hyperactive RyR1 channel that release excess of calcium to the
sarcoplasm [37], initiating a cascade of events that induce hypermetabolism, increased CO2
production and O2 consumption, acidosis, muscle rigidity, tachycardia, and tachypnea among
others [36]. Although not all patients with MHS exhibit a muscular affection, the majority
of CCD patients are susceptible to malignant hyperthermia. Patients with MmD and centro-
nuclear myopathy also exhibit predisposition to MHS linked to RyR1 mutations [36]. Recessive
mutations in RyR1 predominantly associate with MmD and are distributed evenly throughout
the gene [35], but can also cause other phenotypes with less well defined cores on muscle
biopsy [38]. Different molecular mechanisms related to RyR1 mutations have been suggested
to underlay core myopathy. For instance, the “leaky channel hypothesis” suggests that MHS-
and CCD-linked mutations confer hypersensitivity to the RyR1 channel, increasing its activity;
thus, affecting Ca2+ homoeostasis by depletion of the intracellular Ca2+ stores [39]; CCD-
mutations have also shown to impair the Ca2+ permeation through RyR1 channel after activa-
tion, affecting the E-C coupling (“E-C uncoupling hypothesis”) [40] and MmD-linked muta-
tions have been associated with a reduction of the RyR1 protein expression levels [41].
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Additionally to RyR1-related forms, mutations in SEPN1 associate with approximately 50% of
the cases of the most prevalent form of MmD [28]. Selenoprotein-N is a sarcoplasmic glycopro-
tein implicated in several processes including antioxidant defenses and calcium homeostasis
[42]. This is part of the selenoproteins family, which characterize for containing selenocysteine
aminoacids (Sec). Incorporation of Sec to the polypeptide chain in selenoproteins occurs due to a
“redefinition” of the stop-codon UGA during translation, which requires a Sec insertion
sequence (SecIS) in the non-translated 3’UTR region and a Sec redefinition element (SRE) located
adjacent to the UGA codon. Myopathy causing mutations in SEPN1 affects the Sec insertion
efficiency, decreasing the expression of selenoprotein-N, and leading to a deficiency of the
protein [43]. Mutations in SEPN1 have been also pointed as causative of congenital muscular
dystrophy with rigid spine (RSMD), a rare neuromuscular disorder characterized by early spine
stiffness and respiratory deficiency [44].
2.3. Centronuclear myopathy
Centronuclear (CNM) myopathy is a heterogeneous group of congenital myopathies clinically
manifested by myalgia, fatigability and progressive weakness and atrophy of distal skeletal
muscles [45]. Histological markers of the disease are the presence of abnormally high number
of muscle fibers with a central rather than peripheral nuclei distribution (Figure 1), predomi-
nance, and atrophy of type 1 fibers, and a radial arrangement of the sarcoplasmic strands on
oxidative stains [45]. Different forms of CNM have been described according to the inheritance
pattern and clinical manifestations. The X-linked recessive form, calledmyotubular myopathy
(XLMTM), presents as a severe myopathy with marked hypotonia and generalized muscle
weakness in newborn males and exhibit a poor prognosis with the most of patients dying
within the first months of life as a consequence of respiratory failure [46]. A late-onset
myotubular myopathy has been also reported, which presents with milder symptoms during
childhood that worsen after the first or second decade of life and that histologically character-
izes by the presence of “necklace fibers,” a basophilic ring deposit following the contour
of the cell in which myonuclei are aligned [47]. XLMTM is mainly caused by mutations in
the MTM1 gene encoding myotubularin, an ubiquitously expressed lipid phosphatase that
specifically dephosphorylates phosphatidylinositol-3-phosphate and phosphatidylinositol-
3,5-bisphosphate [48]. Myotubularins are implicated in several cell process including endocy-
tosis, membrane trafficking, autophagy, and cytoskeletal dynamics [48, 49] and seem to be
critical for skeletal muscle maintenance as shown in MTM1-deficient mice [50]. More than 200
different XLMTM-linked mutations in myotubularin have been described to date with most of
the mutations predicted to affect its expression and enzymatic activity [51–54]. A mouse model
of XLMTM exhibit T-tubules disorganization, a depression in the sarcoplasmic Ca2+ release by
a reduction in the RyR1 levels and consequent defects in EC-coupling [55].
A classical autosomal-dominant form of CNM, which accounts about 50% of the CNM cases, is
caused by mutations in the DNM2 gene encoding dynamin-2 [56]. The spectrum of dynamin-
2-related CNM severity varies from mild, with late-onset, to severe with neonatal onset [57].
Mild and moderates forms of DNM2-related CNM manifests with delayed motor milestones,
specially walking and climbing stairs, distal muscle weakness, ptosis, and ophthalmoplegia.
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More severe early-onset forms courses with generalized weakness and hypotonia, scoliosis,
Achilles tendon contractures, and jaw opening among other symptoms [56]. Dynamin-2 is a
large GTP-ase that expresses ubiquitously in different tissues and participates in various
intracellular processes including endocytosis, exocytosis, membrane trafficking, and actin
cytoskeleton remodeling among others [58–60]. CNM-causing mutations in dynamin-2 are
clustered in structural domains involved in dynamin’s oligomerization (middle domain) and
lipid-binding (PH domain) [57]. These mutations have shown to increase dynamin basal GTP-
ase activity and enhance oligomerization [61–63]. The impact of CNM-linked mutations on
dynamin-2-dependent processes has not yet been fully understood. In non-muscle cells both,
reduction [64, 65] and absence of effect [66] in clathrin-mediated endocytosis has been
reported. Skeletal muscles of CNM patients exhibit abnormal cytosolic accumulation of
dynamin-2 and other endocytic proteins [67], while impaired actin remodeling and actin-
mediated trafficking was reported in a rodent mammalian model of CNM [68].
Mutations in the BIN1 gene, encoding amphiphysin 2, cause an autosomal-recessive form of
CNM, which presents with a large clinical variability from severe to moderate phenotypes [46].
Currently, BIN1-related CNM manifests with a delay in the acquisition of motor milestones,
difficult to walk, run and climb stairs, diffuse muscle weakness and atrophy and facial
involvement including diplegia, ptosis and ophthalmoplegia [56]. Amphiphysin 2 is a ubiquity
expressed protein that belongs to the BAR-domain family, which acts as sensor of the mem-
brane curvature [69]. At late stages of the clathrin-mediated endocytosis, amphiphysin2 bind
to the invaginated membranes and recruits other proteins to the endocytic machinery includ-
ing dynamin-2 [70]. CNM-causing mutations in BIN1 localizes in its BAR domain affecting its
capabilities to tabulate membranes and in its SH3 domain, producing a partial truncation that
eliminates its interaction with dynamin-2. The later suggests that mutations in amphiphysin-2
disrupt the formation and maintenance of the T-tubule network by impairing membrane
remodeling, leading to CNM [71].
CNM-causing autosomal-recessive mutations have been also reported in the gene encoding
RyR1 [72, 73] and TTN gene, encoding titin [74]. Clinically, RyR1-related CNM patients exhibit
early hypotonia, motor developmental delay, proximal and proximal, facial and ocular muscle
weakness. Histologically, they show a variable prominence of central nuclei, type-1 fiber
predominance and a wide range of intermyofibrillary abnormalities [72, 74]. Most CNM-
linked mutations in RYR1 result in reduced expression of the ryanodine receptor channel [75]
likely suggesting defects in the EC-coupling. Titin is a giant protein (the largest one known)
important in the contraction of the striated muscle. It connects the Z line to the M line in the
sarcomere forming a third filament system important for the structural integrity of the myofi-
bril and for the passive tension in stretched muscle fibers [76]. CNM-causing mutations in titin
produce degradation and truncated versions of the protein in patients [74], likely affecting
muscle stiffness and contractibility. Mutations in titin also associate with cardiomyopathies
[77] and muscular dystrophy [78].
Recently, mutations in the striated muscle preferentially expressed protein kinase SPEG, a
myotubularin-interacting protein, have been related to myotubular centronuclear myopathy
[79, 80]. Mutations in SPEG cause phenotype that range from mild forms of CNM with
moderate hypotonia and weakness to more severe forms with cardiac involvement [79, 80].
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2.4. Congenital fiber-type disproportion myopathy
Congenital fiber-type disproportion myopathy (CFTDM) is defined by an abnormal dispro-
portion between the size of type-1 (slow) and type-2 (fast) muscle fibers, with the type 1 fibers
found to be at least 35–40% smaller than the type 2 ones [81]. This is a critical point for the
diagnosis since other myopathic conditions manifests with fiber type disproportion. Clinically,
CFTDM patients experience mild to severe muscle weakness mainly affecting shoulders, arms,
hips, and thighs. Orthopedic affections such as lordosis, scoliosis, and joint contractures are
usually observed. Approximately, 30% of CFTDM patients exhibit respiratory muscle hypoto-
nia, requiring breathing assistant. Face muscles can also be affected producing long face, high-
arched palate, ptosis, and ophthalmoplegia [1]. Genetically, the most well-established causes of
CFTDM are mutations in TPM3, RYR1, and ACTA1 genes [81]. Mutations in TPM3 are the
most common cause of CFTDM accounting between 20 and 50% of the diagnosed cases [81,
82]. Almost all TPM3 mutations associated with CFTDM are dominant missense changes and
are predicted to impair the interaction between alpha-tropomyosin and actin [82] likely affect-
ing acto-myosin interaction in the cross-bridges cycle and impairing a proper muscle contrac-
tion [83]. Recessive mutations in RYR1 have shown to cause CFTDM accounting 10–20% of the
CFTDM families. The most specific clinical indication of RyR1-related CFTDM is the presence
of ophthalmoplegia and a dramatic disproportion in the size of type 1 fibers (being 50–84%
smaller than type2 fibers) [84]. CFTDM-causing mutations reduce RyR1 protein expression
levels [84], probably impairing channel conductance and EC-coupling. Mutations in ACTA1
linked to CFTDM are less probable compared to ACTA1 mutations in nemaline myopathy, and
account approximately 5% of the CFTDM patients [85]. How mutations in ACTA1 produce
fiber type disproportion is uncertain since it is equally expressed in both, type 1 and type 2
fibers. The pathological mechanism of ACTA1-related CFTDM is also unclear, although it was
reported that one mutation in a residue located in the external surface of alpha actin, in which
a negatively charged residue is replaced by a non-charged one (D294V), impair actin-
tropomyosin association, deregulating acto-myosin interaction, and leading to defects in mus-
cle contraction [86]. Much less frequent causes of CFTDM are mutations in the genes encoding
beta-tropomysoin-2 (TPM2), beta-myosin (MYH7), and selenoprotein-N (SEPN1) [81].
2.5. Myosin storage myopathy
Myosin storage myopathy (MSM) is a rare congenital myopathy caused by mutations in the
gene encoding the slow-skeletal/β-cardiac myosin heavy chain (MYH7), a class II myosin and
major component of the thick filaments. It is primarily expressed in heart but also in skeletal
muscle type-1 fibers [87]. In vivo, myosin forms dimers of myosin heavy chains with two
globular heads attached to a coiled-coil region known as the myosin rod. The head region is
responsible for myosin’s ATPase-activity and actin-binding, while the rod region allows the
incorporation of myosin to the thick filaments [88]. MYH7 mutations are spread along the
different myosin’s domains and according their location associate with different phenotypes.
In this regard, mutations in the N-terminal globular head are linked to cardiomyopathies,
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whereas mutations in the C-terminal rod associate to skeletal muscle myopathies such as MSM
[89]. MSM-linked mutations in MYH7 have shown to alter myosin folding and stability,
impairing sarcomere thick filaments assembly and integrity [88, 90]. MSM clinical phenotypes
are highly variable between patients. It presents with childhood or adult-onset forms with
static or slowly progressive clinical course. Hypotonia and proximal muscle weakness with
delayed motor milestones are common features. Respiratory insufficiency secondary to the
myopathy may occur, with the presence or not of cardiac involvement [1]. Histologically, MSM
characterizes by the sub-sarcolemmal accumulation of β-myosin in type 1 fibers, which can be
observed with hematoxylin-eosin and Gömöri trichrome stains as “hyaline bodies.”
3. Mitochondrial myopathies
Dysfunctions of the respiratory chain, responsible for oxidative phosphorylation and ATP
energy production in the inner mitochondrial membrane, causemitochondrial diseases. These
manifest as multisystem disorders with predominant involvement of muscles and nerves.
When skeletal muscle is affected, the term mitochondrial myopathy is used. In isolated
mitochondrial myopathy without involvement of other tissues, patients can exhibit myalgia,
fatigue, exercise intolerance, proximal and distal muscle weakness, and elevated serum CK
[91]. Other clinical manifestations include the chronic progressive external ophthalmoplegia
(CPEO), in which a slowly progressive paresis of the extra ocular muscles is the most impor-
tant phenotype [92] and severe encephalomyopathy of infancy or childhood, in which brain
and skeletal muscle tissue are involved, producing marked hypotonia, respiratory muscle
weakness, and feeding difficulty [93]. Mitochondrial myopathies may be caused by mutations
in mitochondrial or nuclear DNA. Mitochondrial-DNA encoded cytochrome b [91] and
cytochrome c oxidase [94, 95] are mutated in some forms of isolated mitochondrial myopathy.
Mutations in nuclear DNA that produce deficiency of Coenzyme Q10, an important electron
carrier of the respiratory chain also associate to mitochondrial myopathy [96]. Depletion of
mitochondrial DNA in skeletal muscle, secondary to mutations in nuclear genes (mitochon-
drial depletion syndrome) can also cause mitochondrial myopathy. It mainly affects genes
encoding proteins involved in the maintenance of the mitochondrial deoxy-ribonucleotide
pool, such as thymidine kinase (TK2) [97] or proteins implicated in mitochondrial DNA
replication such as the polymerase gamma 1 (POLG1) [98]. Histologically, mitochondrial
myopathy characterizes by a sub-sarcolemmal and intermyofibrillar accumulation of mito-
chondria in muscle fibers, which responds to compensatory mechanisms due to defects in the
energy production. Upon Gömöri trichrome stain, proliferated mitochondria look as bright red
masses against the blue background of the myofibers, defining the term “ragged red fibers”
(Figure 1). Staining of succinate dehydrogenase (SDH) and cytochrome c oxidase (COX) are
indicative of mitochondrial complexes activity. In SDH-positive biopsies “ragged blue fibers”
can be observed. Staining pattern with normal fibers mixed with ragged blue/red COX-
positive fibers is a histological marker of mitochondrial-DNA-related myopathy [99].
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4. Metabolic myopathies
Metabolic myopathies result from defects in the metabolism of carbohydrates and lipids that
primarily affect skeletal muscle. Defects in energy production are typically manifested by meta-
bolic crisis with generalized muscle weakness, sometimes associated with cardiac and respira-
tory failure [100]. Metabolic myopathies can be classified as glycogen storage and lipid storage
diseases. Among glycogen storage diseases is glycogenosis type II (Pompe disease), an
autosomal-recessive disorder caused by mutations that lead to a deficiency of the lysosomal
enzyme acid α-glucosidase (GAA), responsible for catalyze the hydrolysis of glycogen. Defi-
ciency of GAA produces glycogen accumulation and disruption of tissue architecture in different
tissues, especially in skeletal muscle [100]. The clinical phenotype of Pompe disease ranges from
childhood-onset severe forms to mild adult forms [101]. The most classic childhood form mani-
fests in the first months of life with severe myocardiopathy, generalized hypotonia and muscle
weakness, feeding difficulties, and respiratory failure. The late-onset disease presents with pro-
gressive proximal and axial muscle weakness, leading to alteration in the posture and pattern of
movements [100]. Enzyme replacement therapy allows diminishing the symptoms although
untreated late-onset patients may worsen progressively eventually needing wheelchair and
assisted ventilation [102]. Histological markers of Pompe disease are the presence of huge
basophilic vacuoles inside muscle fibers in childhood-onset forms, and globular cytosolic inclu-
sions with acid phosphatase activity in adult-onset forms of the disease [103]. Other glycogen
storage diseases affecting glycogen degradation are glycogenosis type III (Cori disease), caused
by recessive mutations in the AGL gene that lead to glycogen debranching enzyme deficiency
[104] and glycogenosis type V (McArdle disease), caused by mutations in the PYGM gene that
causemyophosphorylase deficiency [105]. Cori disease patients typically exhibit hypotonia and
distal weakness and may present cardiac and hepatic failure [104]. McArdle disease patients
presents with fatigue and exercise-induced myalgia. In some cases, patients can exhibit
myoglobinuria and acute renal failure due to rhabdomyolysis, as well as higher susceptibility to
malignant hyperthermia [106]. Large glycogen-containing vacuoles typically accumulate at the
sub-sarcolemmal level in McArdle disease biopsies (Figure 1).
Lipid storage myopathies characterizes by abnormal lipid accumulation in muscle fibers due
to fatty acid dysmetabolism. Different forms of lipid storage myopathy have been described
among them primary carnitine deficiency (PCD), multiple acyl-CoA dehydrogenase defi-
ciency (MADD) and neutral lipid storage disease with myopathy (NLSDM) [107]. PCD is
caused by autosomal-recessive mutations in the SLC22A5 gene that encodes the carnitine
transporter OCTN2. Defects in OCTN2 lead to deficiency of carnitine and reduced transpor-
tation of long-chain fatty acids to the mitochondrial matrix, producing cytosolic lipid accumu-
lation and a reduction in the ATP production for β-oxidation [107]. Clinically PCD manifests
with a wide spectrum of symptoms including hypotonia, muscle weakness, and cardiomyop-
athy. Histopathological markers include elevated levels of CK and increased number and size
of lipid droplets, especially in type 1 muscle fibers [107]. MADD is caused by deficiency of
electron-transfer flavoprotein (ETF) or ETF-dehydrogenase (ETFH), two mitochondrial
enzymes that act transferring high-energy electrons produced during the fatty acid β-oxidation
by acyl-CoA-dehydrogenases to the respiratory chain. The clinical phenotype of MADD is
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highly heterogeneous ranging from neonatal-onset forms that manifest with hypotonia, hepa-
tomegaly, hypoglycemia, and metabolic acidosis and later-onset forms that present with prox-
imal muscle weakness often with hepatomegaly, encephalopathy, and episodic lethargy. Like
in PCD, muscle fibers of MAAD patients exhibit increased lipid droplets [107]. NLSDM is
caused by mutations in the PNPLA2 gene, encoding the adipose triglyceride lipase implicated
in the catabolism of stored triglycerides to glycerol and non-esterified fatty acids [108]. Histo-
pathological markers of the disease include neutral-lipid containing vacuoles, stained by oil-
red O in neutrophils and monocytes as well as marked triglyceride storage and cytoplasmic
lipid droplets in muscle sections [108]. NLSDM is clinically characterized by, either, child-
hood- or adult-onset proximal muscle weakness, typically affecting upper limbs, although
distal asymmetrical muscle weakness may also occur, as well as elevated CK serum levels
and cardiomyopathy in some cases [100].
5. Myotonia
Myotonia is a symptom associated to several neuromuscular disorders characterized by a
prolonged contraction or rigidity of the skeletal muscles (delayed relaxation) after voluntary
contraction or electrical stimulation. It is present in congenital myotonia, paramyotonia
congenita, and myotonic muscular dystrophy among others muscular disorders. Congenital
myotonia is a non-dystrophic disorder caused by loss-of-function mutations in the skeletal
muscle chloride channel ClC1 resulting in a reduced sarcolemmal chloride conductance [109].
ClC1 channels are critical players stabilizing resting membrane potential and promoting repo-
larization. Upon propagation of an action potential along T-tubules, an efflux of potassium
ions occur to repolarize membrane potential. Due to the spatial confinement of T-tubules this
efflux leads to an increase in extracellular potassium concentration which tends to produce an
“after-depolarization” that is dampened by chloride conductance under normal conditions.
Mutations in ClC1 reduce chloride conductance, enhancing the sarcolemmal excitability by
accumulation of potassium ions in the transverse tubules [110]. This condition may trigger
spontaneous action potentials explaining the persistent muscle contraction observed in
myotonic patients. Congenital myotonia is classified in autosomal-dominant Thomsen’s dis-
ease and autosomal-recessive Becker’s myotonia. The first is a moderate form of myotonia
with no progressive symptoms, allowing to the patients a relatively normal life expectancy.
Becker’s myotonia is an early-onset more severe form of the disease that presents with pro-
nounced myotonia, myalgia, transient episodes of generalized weakness and muscular hyper-
trophy [110]. Predominance and hypotrophy of type 2 fibers and increased endomysial
connective tissue are usually observed in biopsies of congenital myotonia patients.
Paramyotonia congenita is a non-dystrophic muscular disorder caused by autosomal-
dominant mutations in the SCN4A gene encoding the pore-forming alpha-subunit of the
skeletal muscle sodium channel (Nav1.4) [111]. Nav1.4 mutations cause channel gain of
function, producing abnormal persistent sodium currents that lead to the myotonic phenotype
[111]. Paramyotonia congenita manifests with early-onset generalized weakness and “myo-
tonic discharges” that produce an exacerbated stiffness by repeated muscle contraction.
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Patients also exhibit an extreme sensitivity to cold that worsens the symptoms [111]. Myo-
tonic muscular dystrophy is the most common cause of muscular dystrophy in adults and
results from expression of RNAs that contain expanded nucleotide repeats in the 30
untranslated region of two different genes leading to two forms of the disease. Myotonic
dystrophy type 1 (DM1) that results from an expansion of CTG repeats in the DMPK gene
encoding myotonin-protein-kinase and myotonic dystrophy type 2 (DM2) caused by an
expansion of CCTG repeats in the zinc finger 9 (ZNF9) gene. These mutant transcripts form
hairpins, imperfect double-stranded structure that lead to deregulation of important RNA-
binding proteins such as muscleblind-like protein 1 (MBNL1), which are retained in nuclei
forming toxic nuclear foci that impair gene expression [112]. Aberrant expansion of nucleo-
tide repeats has shown to deregulate alternative splicing of pre-mRNA for ClC1 channel,
affecting chloride conductance in skeletal muscle, leading to the myotonic phenotype [113].
Both DM1 and DM2 exhibit an autosomal-dominant inheritance pattern. Clinical presenta-
tion includes muscle wasting, progressive weakness, myotonia, cataracts, and multi-organ
involvement affecting heart, brain, and endocrine system [112]. DM1 patients manifest more
severe myotonia with prominent distal muscle involvement and a severe congenital form
with mental retardation. DM1 is characterized by the phenomenon of “anticipation,” by
which the disease has an earlier onset and more severe course in subsequent generations
[114]. In DM2 patients, proximal muscles are more affected; exhibiting milder myotonia with
no “anticipation” [115]. Histological features in myotonic dystrophy include a high number
of internalized nuclei, disproportion in fiber diameter with type 1 fibers atrophy, baso-
philic regenerating fibers, fibrosis, and adipose deposition. Specifically in DM2 biopsies
atrophic type 2 fibers with pyknotic nuclear clumps are often observed [112, 116].
6. Muscular dystrophies
Muscular dystrophies (MD) are a heterogeneous group of neuromuscular disorders that result
in progressive weakness and degeneration of skeletal muscles, affecting limbs, axial, and facial
muscles. In some forms of the disease, heart and other organs are also affected [117]. The onset
of MD is typically in early childhood, although the symptoms can appear in infancy up to
middle age or later. The estimated incidence of MD is 1:2000 live births. Histopathological
markers of MD are a diffuse variation in the size of fiber types, necrosis (with or without
phagocytosis), fiber regeneration, fibrosis, and atrophy. Inflammatory response is present in
some forms of MD (Figure 1). Elevated serum levels of CK are typically observed in MD
patients [118]. MD are caused by mutations in genes that encode a wide variety of proteins,
including transmembrane and membrane-associated proteins, extracellular matrix proteins,
cytoplasmic enzymes, and nuclear envelope proteins [119]. More than 30 different forms of
MD have been described, which differ in their genetic background, primarily affected muscles,
the age of onset of the symptoms and the degree of weakness and progression. Some of the
most common MDs are described below.
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6.1. Duchenne and Becker muscular dystrophy
Duchenne and Becker muscular dystrophies are two related X-linked recessive muscle disor-
ders caused by mutations in the DMD gene encoding dystrophin, a critical component of the
dystrophin-glycoprotein complex (DGC), a molecular scaffold that links fiber cytoskeleton to
the extracellular matrix, providing mechanical stability to skeletal muscle [119]. Defects in
DGC lead to mechanical stress during muscle contraction, producing sarcolemmal damage,
abnormal Ca2+ homeostasis and consequent fiber necrosis [119]. Duchenne is the most com-
mon muscular dystrophy in childhood affecting approximately 1:3500 newborn males [117].
Duchenne-causing mutations usually lead to a pronounced reduction or complete absence of
dystrophin, while Becker mutations have a less dramatic effect in dystrophin expression.
Occasional muscle fibers positive for dystrophin can be found in about 50% of DMD patients
called “revertant fibers,” where dystrophin expresses in discrete domains with a “patchy
distribution” that not influence the clinical phenotype [120]. Duchenne patients present early-
onset dystrophy, delayed acquisition of motor milestones and a rapid progression of muscle
weakness that usually leads them to need wheelchair by adolescence. Becker patients manifest
milder symptoms with muscle weakness becoming later in childhood or in adolescence with a
much slower progression. Both cases are usually associated with cardiomyopathy [121]. Insu-
lin resistance and other metabolic alterations have also been observed in Duchenne and Backer
patients [122].
6.2. Limb-girdle muscular dystrophies
Limb-girdle muscular dystrophies (LGMD) are a heterogeneous group of rare muscular disorders
characterized by progressive proximal muscle wasting, predominantly affecting hip and shoul-
ders. Clinical manifestations are broad, ranging from severe forms with rapid onset and progres-
sion to slowly progressive late-onset milder forms [123]. According to the inheritance pattern,
LGMD can be classified in autosomal-dominant forms (LGMD1) and autosomal-recessive forms
(LGMD2). Letters are added consecutively allowing to classify LGMD according to when indi-
vidual genes were identified [117].
LGMD1 are usually adult-onset mild forms of the disease. Among them, LGMD1A is caused by
mutations in the MYOT gene encoding myotilin, a Z-disk associated alpha-actinin-binding
protein involved in the structural integrity of sarcomeres [123]. Patients exhibit proximal and
distal weakness and occasional respiratory and cardiac involvement. LGMD1B is caused by
mutations in the LMNA gene, encoding the nuclear membrane protein lamin A/C, implicated
in several roles including mechanical maintenance of the nuclear membrane and gene regulation.
Clinical manifestations of this “laminopathy” include proximal weakness, cardiac arrhythmias,
and dilated cardiomyopathy [123]. LGM1C is caused by mutations in the CAV3 gene that
encodes caveolin-3, a muscle-specific sarcolemma protein component of caveolae membranes,
specialized lipid rafts involved in plasma membrane maintenance, vesicular trafficking, and
signal transduction [124]. Patients exhibit moderate proximal weakness, calf hypertrophy, and
muscle cramps associated to exercise [123]. LGMD1D is caused by mutations in DNAJB6, a
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member of the “DNAJ family,” molecular chaperones involved in protein folding. LGMD1E
associates to mutation in the DES gene encoding desmin, a component of the intermediate
filaments that provides structural support to the sarcomere [123]. LGMD1F is caused by muta-
tions in the transportin 3 gene (TNPO3), a nuclear receptor for serine/arginine-rich proteins.
Mutations in the RNA-processing proteinHNRPDL cause LGMD1G [123].
Recessive LGMD are more frequent forms of the disease. Among them LGMD2A is the most
prevalent LGMD worldwide accounting for up to 30% cases and is caused by mutations in the
CAPN3 gene encoding calpain 3, a Ca2+-dependent non-lysosomal cysteine protease impli-
cated in sarcomere organization and maintenance in mature muscle fibers. Most of the CAPN3
mutations result in autolysis and impaired proteolytic activity of calpain 3 [125]. Pathological
features of the disease are progressive weakness and atrophy of the shoulder and pelvic girdle
musculature, raised levels of serum CK and wasting and regeneration of muscle fibers in
biopsy [126]. Recessive mutations in the DYSF gene encoding dysferlin cause LGMD2B.
Dysferlin is a ubiquitous transmembrane protein implicated in Ca2+-dependent resealing of
the sarcolemma after injury [127]. Dystrophy-causing dysferlin mutations produce a drastic
deficiency or complete absence of the protein; however, reduced dysferlin expression can also
be observed in other muscular dystrophies secondary to mutations in other related genes [118].
LGMD2B account 15–25% of the LGMD2 cases and presents with slowly progressive proximal
weakness that usually begin in the first or second decade of life and eventually lead to
wheelchair dependence. Very highly elevated CK serum levels, nuclei internalization, muscle
fibers necrosis and regeneration, and inflammatory infiltrates are typically observed. Other
typical form of “dysferlinopathy” is Miyoshi myopathy, which is an adult-onset, more distal
form that mainly affects posterior muscles of legs [117].
LGMD 2C-2F are referred as “sarcoglycanopathies” and are caused for loss of function muta-
tions in the genes encoding alpha, beta, gamma, or delta-sarcoglycans, respectively. These are
transmembrane proteins members of the sarcoglycan-complex, critical component of the DGC
implicated in connecting cytoskeleton to the extracellular matrix providing mechanical stability
to the skeletal muscle [128]. Sarcoglycanopathies have a childhood onset and typically manifest
with rapid or slowly progressive proximal weakness involving both, cardiac and respiratory
functions [123].
The “dystroglycanopathies” group a number of recessive LGMD (2I, 2K, 2M, 2N, 2O, 2P)
linked to mutations in six genes implicated in the glycosylation of alpha-dystroglycan, critical
component of the DGC: fukutin-related-protein gene (FKRP) linked to LGMD2I [129]; O-
mannosyl-transferase 1 gene (POMT1) linked to LGMD2K [130]; fukutin gene (FKTN) asso-
ciated to LGMD2M [131]; O-mannosyl-transferase 2 gene (POMT2) linked to LGMD2N [132];
protein O-linked-mannose beta-1,2-N-acetylglucosaminyltransferase 1 (POMGnT1) associ-
ated to LGMD2O [133] and the dystroglycan gene itself (DAG1) linked to LGMD2P [134].
Abnormal glycosylation of alpha-dystroglycan inhibits its binding to extracellular matrix pro-
teins, impairing skeletal muscle stability. Dystroglycanopathy-causing mutations produce a
wide spectrum of dystrophic phenotypes ranging from mild forms such as those observed in
LGMD to more severe congenital muscular dystrophies (see below) [135].
LGMD2T is caused by mutations in the GDP-mannose pyrophosphorylase B gene (GMPPB),
which catalyzes the conversion of mannose-1-phosphate and GTP to GDP-mannose, consequently
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causing hypoglycosylation of α-dystroglycan [123]. LGMD2T patients exhibit dystrophy with
intellectual disabilities [136]. Mutations in the isoprenoid synthase domain containing gene
(ISPD) also impair dystroglycan glycosylation leading to LGMD2U and also to the severeWalker
Warburg syndrome [137] (see below).
LGMD2J is caused by mutations in the gene encoding the giant sarcomeric protein titin (TTN),
mainly clustered in the C-terminal M-line-linked region of the protein, interferingwith its structure
and function [138]. Mutations in the anoctamin 5 gene (ANO5) cause LGMD2L, an adulthood-
onset disease that presents with asymmetric muscle weakness, pain after exercise and elevated CK
levels [123]. LGMD2Q, an early-onset non-progressive form of LGMD is caused by mutations in
the gene encoding plectin (PLEC1) [123], a ubiquitously expressed protein linking actin microfila-
ments, microtubules and intermediate filaments [139]. Autosomal-recessive mutations in the DES
gene (see above) determine LGMD2R, which may present cardiac involvement [123].
LGMD2S is caused bymutations in the transport protein particle complex 11 gene (TRAPPC11),
a transport protein involved in anterograde membrane trafficking from the endoplasmic reticu-
lum (ER) to the ER-to-Golgi; this form shows childhood onset ataxia, and intellectual disabilities
[143]. A form of adulthood-onset Pompe’s disease has also been classified as LGMD2V [123]
(see Section 4).
LGMD2W caused by mutations in the LIM and senescent cell antigen-like-containing domain
protein 2 gene (LIMS2/PINCH2), that regulates cell shape and migration, presents as a
childhood-onset LGMD2 with calf and tongue hypertrophy and severe quadriparesis [141].
Mutations in the Popeye-domain-containing 1 gene (POPDC1) alter membrane trafficking
and produce LGMD2X [142], which associates with atrio-ventricular conduction blockage
[144]. Mutations in the torsinA-interacting protein 1 gene (TOR1AIP1) encoding the lamina-
associated polypeptide 1B (LAP1B) cause LGMD2Y [142, 144]. LGM2DZ is caused by muta-
tions in the POGLUT1 gene [142] encoding O-glucosyltransferase 1, an enzyme involved in
Notch-posttranslational modification and function, impairing muscle regeneration mediated
by Notch. Patients exhibit typical features of LGMD2 and show reduced glycosylation of α-
dystroglycan [145].
LGMD2G and LGMD2H are the rarest forms of LGMD2. LGMD2G is caused by mutations in
the TCAP gene that encodes telethonin, a titin-interacting protein that links titin to other Z-
disk proteins supporting sarcomere assembly and muscle stretching [146]. Clinical manifesta-
tions include adolescence-onset limb girdle weakness and cardiomyopathy susceptibility
[123]. LGMDH is a late-onset disease characterized by proximal weakness and atrophy caused
by mutations in the TRIM32 gene encoding a ubiquitous E3 ubiquitin ligase involved in
proteasome degradation of multiple targets, including actin [147].
6.3. Congenital muscular dystrophies
Congenital muscular dystrophies (CMD) include a number of neuromuscular disorders with
onset at birth or early infancy that manifest with generalized hypotonia, hyperlaxitud and
predominantly proximal weakness leading to pronounced head drop in most cases. Clinical
course is slowly progressive but can evolve to severe retractions leading to skeletal deformations.
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Usual cardiomyopathy and respiratory failure are observed and central nervous system involve-
ment in the most severe cases [148]. Histological markers of CMD include abnormal variation of
fiber size associated with split fibers, and in some cases with hypercontracted fibers, nuclei
internalization and increase of connective and adipose tissue [148]. One of the most common
CMD ismerosin-deficient-CMD caused bymutations in the LAMA2 gene encoding laminin-α2
chain (merosin) an extracellular matrix protein, major component of the basement membrane
whose main function is link the extracellular matrix to the DGC. Mutations in LAMA2 can result
in a total or partial reduction of the protein levels, being the first cases more severe exhibiting
progressive respiratory insufficiency, brain involvement and white matter abnormalities [149].
Other common forms of CMD are those related with defects in one of the three genes encoding
collagen 6A (COL6A1, COL6A2, COL6A3). Collagen 6A is an important component of the
extracellular matrix which forms a microfibrillar network that anchors the surface of cells with
the interstitial connective tissue playing an important role in mediating cell matrix interactions
due to its association with several matrix proteins [150]. Mutations in COL6A genes can cause
three muscular disorders: Ulrich-CMD, Bethlem myopathy, and myosclerosis myopathy.
Ullrich-CMD is a severe syndrome with neonatal onset that presents with hyperlaxity associ-
ated with proximal contractures in the spine (kyphosis), elbows, and knees and congenital hip
dislocation. Children may never walk or walk and then lose this ability by the end of the first
decade due to the progression of contractures and weakness. Respiratory function progres-
sively declines over time leading to night-time respiratory failure and death [151]. Bethlem
myopathy is a milder form with autosomal-dominant inheritance characterized by slowly
progressive muscle weakness and wasting, distal hyperlaxity, and joint contractures and some
patients exhibiting respiratory failures [153]. Myosclerosis myopathy is a rarest form of the
disease with autosomal-recessive inheritance characterized by toe walking and calf contrac-
tures in childhood, and progressive contractures of all joints in the adult life [151].
Another severe form of CMD is the Walker-Warburg syndrome, a “dystroglycanopathy”
mainly caused by recessive mutations in POMT1 and POMT2 [152]. It manifests with a
dystrophic phenotype accompanied by retinal and brain malformations with most of the
syndromic children dying in the first 3 years of life due to respiratory failure, seizures, hyper-
thermia, and ventricular fibrillation [153].
6.4. Facioscapulohumeral muscular dystrophy (FSHD)
FSHD is one of the most prevalent adult muscular dystrophies with an estimated incidence of
1:8000 live births worldwide [154]. It presents with slowly progressive asymmetric and
descending weakness, initially affecting face (facio), scapula (scapulo), and upper arms
(humeral), followed by weakness of the distal lower extremities and pelvic girdle [155]. Symp-
toms typically begin during the first or second decade of life [155]. There are no FSHD-specific
histopathological markers in biopsy examination but dystrophic features such as fibrosis,
muscle fiber hypertrophy, and central nucleation are present. Endomysial inflammation can
be observed in up to one-third of FSDH biopsies [156]. Ninety-five percent of cases are
inherited in an autosomal-dominant way and associated with a deletion of a key number of
D4Z4 macrosatellite repeats in the 4q35 subtelomeric region in the chromosome 4 (FSHD1).
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The remaining 5% cases (FSHD2) have no deletion on chromosome 4q35 and have a variable
inheritance pattern [155]. Loss of the D4Z4 repetitive elements leads to decreased methylation
and opening up of the chromatin structure, allowing the expression of the DUX4 gene encoding
double homeobox 4, a normally repressed transcriptional regulator. As reported by Lemmers and
collaborators in 2010, the existence of single nucleotide polymorphisms in the region distal to
the last D4Z4 repeat appears to create a poly-adenylation site that activates DUX4, leading to a
“toxic gain of function” that cause FSHD1 disease [157]. In FSHD2 no deletions, but yet loss of
methylation in the D4Z4 region of chromosome 4q35 also lead to DUX4 abnormal expression
[158] suggesting a common pathological mechanism in both FSHD.
6.5. Emery-Dreifuss muscular dystrophy
Emery-Dreifuss muscular dystrophy (EDMD) is an early-onset skeletal myopathy character-
ized by slowly progressive muscular weakness, joint contractures, spine rigidity, and heart
disease [159]. Different types have been described, distinguished by their inheritance pattern in
X-linked, autosomal-dominant, and autosomal-recessive forms. Overall prevalence of EDMD
is unknown, although X-linked appear to be the most prevalent form affecting an estimated of
1:100,000 individuals [159]. EDMD is classified as a “laminopathy” caused mainly by muta-
tions in the EMD gene encoding emerin and in the LMNA gene encoding lamin A/C. While
EMDmutations associate to the X-linked form of EDMD, LMNAmutations are responsible for
most of the autosomal cases [159]. Emerin and lamin A/C are important components of the
nuclear envelope and defects in these genes could impair diverse functions including gene
expression, cell signaling, nuclear structure and chromatin architecture [159, 160]. There are no
clear histological markers in EDMD, but dystrophic features such as fiber size disproportion,
nuclei internalization, increase of endomysial connective tissue, necrosis, and regeneration are
usually observed (Figure 1). A reduced expression of emerin or lamin A/C in muscle tissue,
fibroblasts or blood can usually confirm the diagnosis of EDMD [161].
7. Conclusions
An incredible large spectrum of hereditary myopathies has been described at date and only
some of them have been commented in this chapter. Although hereditary myopathies are
cataloged as “rare diseases” due to their relatively low prevalence, the sum of the different
forms of hereditary myopathies makes these a relatively common health problem that affect
the life quality of patients with complications that can lead to death in the most severe cases.
Thanks to the improvement of technology, in the last decade, it has been possible to know a
still growing number of genes causative of hereditary myopathies, which contributes to the
classification and diagnosis of these disorders. Because defects in the same gene can be the
cause of various hereditary myopathies and because the same myopathic phenotype can
derive from mutations in different related genes, it is important to know and understand all
aspects of the disease to give a successful diagnosis and an adequate management of the
symptomatology.
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